Code Bio: Code Bio Launches with $75M to Disrupt Gene Therapy Space
Code Bio, a biotechnology company leading the way in targeted non-viral delivery of generic medicines, closed a $75 million Series A financing round on Tuesday.
Read full article »
Code Bio is a Pennsylvania-based biotechnology company that develops and commercializes non-viral gene therapies for the treatment of rare diseases.
Read more